Camizestrant combination improves progression-free survival Trial to continue as planned after interim analysis Results "material positive surprise," say Barclays analysts Feb 26 (Reuters ...

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

[BEIJING] AstraZeneca will invest US$2.5 billion in a new research centre in Beijing, in a major show of commitment to China just months after the company’s top executive there was detained by ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D center together with major research and manufacturing agreements. [Photo ...